Our Board of Directors is comprised of seasoned industry leaders with a solid range of life science, technology and business expertise. The Board brings this experience and perspective to guide the success of IntegenX® products and business strategy.
David L. Barker, Ph.D.
Dr. David L. Barker served as Vice President and Chief Scientific Officer at Illumina, Inc. from 2000 through 2006. Dr. Barker was Vice President and Chief Science Advisor at Amersham Biosciences (now part of GE Healthcare) from 1998 to 2000. From 1988 to 1998, he held senior positions, including Vice President of Research and Business Development, at Molecular Dynamics, Inc., until its acquisition by Amersham. In his academic career, Dr. Barker conducted interdisciplinary research in neurobiology as a postdoctoral fellow at Harvard Medical School, Assistant Professor at the University of Oregon, and Associate Professor at Oregon State University.
Dr. Barker also currently serves on the boards of directors of Cell Biosciences, BioNanomatrix, Integrated Diagnostics, and NextBio, and is a scientific advisor to Illumina, GenVault, Diagnostics for the Real World, BiOptix, and DNA Direct.
Dr. Barker holds a B.S. with honors in Chemistry from the California Institute of Technology and a Ph.D. in Biochemistry from Brandeis University.
James C. Blair, Ph.D.
Partner, Domain Associates
Dr. James C. Blair has been a Partner of Domain since its founding in 1985. Dr. Blair has over 40 years experience with venture and emerging growth companies. In the course of this experience, he has been involved in the creation and successful development at the Board level of over 40 life sciences ventures, including Amgen, Aurora Biosciences, Amylin Pharmaceuticals, Applied Biosystems, Dura Pharmaceuticals, GeneOhm Sciences, Molecular Dynamics, Nuvasive, Pharmion and Volcano. Present board memberships include Cadence Pharmaceuticals, Cell Biosciences, Clovis Oncology, Inc., CoDa Therapeutics, Five Prime Therapeutics, GenVault, Helixis, Meritage Pharma, IntegenX, NeuroPace, and Zogenix.
A former managing director of Rothschild Inc., Dr. Blair was directly involved at a senior level with Rothschild/New Court venture capital activities from 1978 to 1985. From 1969 to 1978, he was associated with F.S. Smithers and Co. and White, Weld and Co., two investment banking firms actively involved with new ventures and emerging growth companies. From 1961 to 1969, Dr. Blair was an engineering manager with RCA Corporation, during which time he received a David Sarnoff Fellowship.
Dr. Blair currently serves on the Board of Directors of the Prostate Cancer Foundation, and he is on the Advisory Boards of the Department of Molecular Biology at Princeton University, the Department of Biomedical Engineering at the University of Pennsylvania, the USC Stevens Institute for Innovation, and the Division of Chemistry and Chemical Engineering at the California Institute of Technology.
Dr. Blair received a B.S. in Engineering from Princeton University and both M.S.E. and Ph.D. degrees from the University of Pennsylvania.
Ron Eastman joined Essex Woodlands in the Palo Alto office in 2006 and is a Managing Director. Mr. Eastman has over 30 years of experience in building healthcare businesses. He has helped build three private healthcare companies—Geron, HCORP, and Rinat Neuroscience. Under his leadership, Geron grew from a venture-backed startup to a publicly traded pioneer in the fields of regenerative medicine and cancer. HCORP quickly established itself as the technology and market leader in the emerging field of hospital-based, interactive patient services and was sold to a diversified competitor. Most recently, at Rinat, a private biotech company spun out of Genentech with the support of Essex Woodlands in late 2001, Mr. Eastman led the effort to build the first company dedicated to discovering and developing large molecule drugs for treating nervous system disorders. Rinat was acquired by Pfizer for $500M in 2006. Mr. Eastman began his career at American Cyanamid Company, where he spent 15 years managing various pharmaceutical products, divisions and subsidiaries in the U.S. and overseas.
Mr. Eastman holds a B.A. from Williams College and an M.B.A. from Columbia University.
Mr. Grever joined Qbase in early 2012 after serving 24 years with the FBI, where he held increasingly responsible leadership positions since starting as a Special Agent in 1988. In 2008, he was appointed as Executive Assistant Director of the FBI Science and Technology Branch (STB). In this key role, he was accountable for all forensic, biometric, and applied technology support to the U.S. law enforcement and intelligence communities delivered by the FBI Laboratory, Criminal Justice Information Services (CJIS), and Operational Technology Divisions. In 2007, Mr. Grever was selected as the deputy to the STB Executive Assistant Director, following his service as Deputy Assistant Director in charge of the STB’s Special Technologies and Applications Office, responsible for developing and delivering innovative technical and analytical tools and capabilities.
Mr. Grever earned a Bachelor of Science degree in Police Administration and Management from the University of Louisville, as well as a Master of Science degree in Computer Information Systems from Strayer University. He received a Presidential Meritorious Executive Rank Award in 2011 and the National Intelligence Distinguished Service Medal in 2012.
Dr. Dennis Harris is a co-founder of IntegenX and is an experienced executive who has spent the majority of his career developing and implementing business strategies for life science companies to maximize their research and development efforts and to enhance their ability to bring innovation to customers. In his various roles, he has initiated and led successful portfolio acquisitions and negotiated technology collaborations. Prior to IntegenX, he served as Chief Scientific Officer at Millipore since 2006. He was Vice President and Chief Scientific Officer at Serologicals Corporation from 2004 to 2006 and Executive Vice President of Research and Development at Vitra Bioscience from 2002 to 2003. He served as Senior Vice President at Aclara Biosciences, Inc., a developer of microfluidics and gene and protein analysis technologies. Prior to Aclara, he held positions of increasing responsibility at Amersham Pharmacia Biotech (now part of GE Healthcare) including Vice President of Research and Development. Dr. Harris has extensive background in DNA sequencing and laboratory automation systems.
Dr. Harris currently serves on the board of directors for IntegenX, and also serves on the board of directors for Biolog, Inc.
Dr. Harris earned his B.SC. Hons. in Biochemistry and Ph.D. from the University of Sussex, England. He has authored 17 papers.
Stevan Jovanovich, Ph.D.
Co-Founder of IntegenX
President and Chief Executive Officer
Dr. Stevan Jovanovich is President and CEO of IntegenX, a company he co-founded in 2003 to better optimize sample preparation for the life sciences. At IntegenX he has been the Principal Investigator on over $10 M of grants and contracts focused on DNA sequencing, biodefense, and forensics. He currently leads a growing team of talented professionals dedicated to commercializing the technology.
Dr. Jovanovich is an internationally recognized expert in microfluidics and an experienced global commercial leader. Before co-founding IntegenX, Dr. Jovanovich was Vice President of Global Research at Amersham Biosciences where he led a team of 120 scientists and engineers and drove multiple business projects across six international sites.
Prior positions include Science Director at Amersham Biosciences, Manager of Advanced Research at Molecular Dynamics, Staff Scientist at Lawrence Berkeley National Laboratory, Director of Microbiology at AbTox Inc, and founder of Molecular Solutions.
Dr. Jovanovich has proven expertise in microbiology, molecular genetics, microbial physiology, object-oriented programming, robotics, genomics, systems biology, and instrument and systems development. He is author of over 20 papers and an inventor on over 20 US patents. He holds Bachelor of Science degrees in Physics and Life Sciences from MIT, and a Ph.D. in Microbiology from University of California at Davis.
André F. Marion retired from the Perkin-Elmer Corporation as President of the Applied Biosystems Division in 1995. Mr. Marion was the Chairman of the Board, Chief Executive Officer, and President of Applied Biosystems, Inc. at the time of its merger with Perkin-Elmer in 1993. As one of the founders of Applied Biosystems, Mr. Marion served as its Chairman of the Board from 1987, President and Chief Executive Officer from 1986, Chief Operating Officer from 1983 to 1986, and was Vice President of Engineering from the founding of the Company in 1981 until 1983. Prior to founding Applied Biosystems, Mr. Marion held various Research and Development managerial positions at Hewlett-Packard.
Mr. Marion currently serves on the board of directors of several private companies.
A native of France, he holds an engineering degree from the French Ecole Nationale Supérieures d’Ingénieurs Arts et Métiers in both mechanical and electronic engineering.
Dr. Mostafa Ronaghi joined Illumina in 2008 following their acquisition of Avantome, a sequencing technology start-up that he co-founded in 2007. From 2002 to 2008, Dr. Ronaghi was a principal investigator at the Stanford Genome Technology Center where he focused on developing molecular diagnostic applications. He is an experienced entrepreneur, having co-founded four successful life sciences companies. In 2004, he co-founded NextBio, which develops and markets a discovery platform for life science data, and serves as chairman of their Scientific Advisory Board. In 2001, he co-founded ParAllele BioScience, which developed highly multiplexed technology for genetic testing and was acquired by Affymetrix in 2005. In 1997, he co-founded Pyrosequencing AB (renamed Biotage), and led the company to a successful initial public offering in 2000 on the Stockholm Stock Exchange.
Dr. Ronaghi also serves on the board of directors of NextBio and Aurora Biofuels.
Dr. Ronaghi earned his Ph.D. from the Royal Institute of Technology in Sweden. He holds more than 20 pending and issued patents and has written over 50 peer-reviewed publications in journals and books.
Benjamin Schapiro founded QuestMark Partners in 1998. Prior to QuestMark, Mr. Schapiro began his career in investment banking at Robert Garrett & Sons, which merged into Alex. Brown & Sons. Throughout his 32-year tenure, Mr. Schapiro’s efforts encompassed institutional, international and private client accounts, real estate finance, corporate finance, merger and acquisition transactions as well as public and private investing in emerging growth companies.
Mr. Schapiro currently is or has been a member or active observer on the boards of Align Technology (ALGN), AngioScore, Aspect Medical Systems (ASPM), eHealth (EHTH), Fortify Software (acquired by HP), GeneOhm Sciences (acquired by Becton Dickinson), GenVault (acquired by IntegenX), Hospital Partners of America, Kodiak Networks, Mformation, Nimblefish (acquired by RR Donnelley), Rhythm NewMedia, SeniorHealth, TissueLink Medical (now Salient Surgical Technologies, acquired by Medtronic), Vapotherm and Xirrus. He has served as chairman, vice chairman and trustee or board member of a number of endowment funds, charitable organizations and professionally managed portfolios.
Mr. Schapiro earned a degree in Economics from Randolph-Macon College.